secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001493152-25-024174
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M
----------------------------------------------------------------------------

- Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M
- Cash $405K; working capital deficit $47.5M at Sep 30 vs $1.5M at Dec 31, 2024
- Crown Medical appointed Special Counsel to recover $50M+ net A/R; first settlement completed
- BE-Smart esophageal cancer test validated by Mayo Clinic; commercialization rollout underway
- Nebula Genomics pro-forma profitable; strategic M&A discussions ongoing

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/0001493152-25-024174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315225024174/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer